Cited by 4,262Protein Degradation and InhibitorsChromatin Remodeling and CancerEpigenetics and DNA Methylation

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Selective inhibition of BET bromodomains

Open access

Filippakopoulos, Panagis, Qi, Jun, Picaud, Sarah, Shen, Yao, Smith, William B., Fedorov, Oleg, Morse, Elizabeth M., Keates, Tracey, Hickman, Tyler T., Felletar, Ildiko, Philpott, Martin, Munro, Shonagh, McKeown, Michael R., Wang, Yuchuan, Christie, Amanda L., West, Nathan, Cameron, Michael J., Schwartz, Brian, Heightman, Tom D., La Thangue, Nicholas, French, Christopher A., Wiest, Olaf, Kung, Andrew L., Knapp, Stefan, Bradner, James E.·2010·Nature

DOI 10.1038/nature09504PMC PMC3010259

Open this paper in CoChat — free account

Abstract

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09504

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 273
Retracted
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,141
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 751

Flagged first, then by citations

Show all 42 references

2 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Sueoka, H., Komatsu, H., Kobayashi, H. & Ehara, S. Thienotriazolodiazepine Compounds and Medicinal Uses Thereof 1–50 (Yoshitomi Pharmaceutical Industries, Ltd, 1998)

Sorted by citations

Items 501–600 of 1,029

An iridium( iii )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Role and potential for therapeutic targeting of MYB in leukemia
Pattabiraman, D. R., & Gonda, T. J. (2012) · Leukemia · doi:10.1038/leu.2012.225 · Cited by 138
Chromatin deregulation in disease
Mirabella, A., Foster, B. M., & Bartke, T. (2015) · Chromosoma · doi:10.1007/s00412-015-0530-0 · Cited by 139
LncRNA MAGI2-AS3 Is Regulated by BRD4 and Promotes Gastric Cancer Progression via Maintaining ZEB1 Overexpression by Sponging miR-141/200a
Li, D., Wang, J., Zhang, M., Hu, X., She, J., Qiu, X., Zhang, X., Xu, L., Liu, Y., & Qin, S. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.11.003 · Cited by 138
The contemporary management of cancers of the sinonasal tract in adults
Thawani, R., Kim, M. S., Arastu, A., Feng, Z., West, M. T., Taflin, N. F., Thein, K. Z., Li, R. T., Geltzeiler, M. N., Lee, N. Y., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21752 · Cited by 138
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Zhang, G., Plotnikov, A. N., Rusinova, E. V., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M. H. J., & Zhou, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401334s · Cited by 137
Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer
Gong, F., Chiu, L.-Y., & Miller, K. M. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006272 · Cited by 137
Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrityPreprint
Kim, J. J., Lee, S. Y., Gong, F., Battenhouse, A. M., Boutz, D. R., Bashyal, A., Refvik, S. T., Chiang, C., Xhemalçe, B., Paull, T. T., et al. (2019) · Genes & Development · doi:10.1101/gad.331231.119 · Cited by 138
BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling
Andrieu, G. P., Tran, A. H., Strissel, K. J., & Denis, G. V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0559 · Cited by 136
BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange–like syndrome
Study, D. D. D., Olley, G., Ansari, M., Bengani, H., Grimes, G. R., Rhodes, J., von Kriegsheim, A., Blatnik, A., Stewart, F. J., Wakeling, E. L., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0042-y · Cited by 136
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Özer, H. G., El‐Gamal, D., Powell, B., Hing, Z. A., Blachly, J. S., Harrington, B. K., Mitchell, S. R., Grieselhuber, N. R., Williams, K., Lai, T.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0902 · Cited by 136
A caged E3 ligase ligand for PROTAC-mediated protein degradation with light
Kounde, C. S., Shchepinova, M. M., Saunders, C. N., Muelbaier, M., Rackham, M. D., Harling, J. D., & Tate, E. W. (2020) · Chemical Communications · doi:10.1039/d0cc00523a · Cited by 136
Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis
Nishida, J., Momoi, Y., Miyakuni, K., Tamura, Y., Takahashi, K., Koinuma, D., Miyazono, K., & Ehata, S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0491-2 · Cited by 135
A Plasmodium Falciparum Bromodomain Protein Regulates Invasion Gene Expression
Josling, G. A., Petter, M., Oehring, S. C., Gupta, A. P., Dietz, O., Wilson, D. W., Schubert, T. E. O., Längst, G., Gilson, P. R., Crabb, B. S., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.05.009 · Cited by 135
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Leal, A. S., Williams, C. R., Royce, D. B., Pioli, P. A., Sporn, M. B., & Liby, K. T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.021 · Cited by 135
Ectopic protein interactions within BRD4–chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma
Alekseyenko, A. A., Walsh, E. M., Zee, B. M., Pakozdi, T., Hsi, P. T., Lemieux, M. E., Cin, P. D., Ince, T. A., Kharchenko, P. V., Kuroda, M. I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702086114 · Cited by 135
Self-citation
Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations
Sholl, L. M., Nishino, M., Pokharel, S., Mino-Kenudson, M. A., French, C. A., Janne, P. A., & Lathan, C. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000545 · Cited by 134
Self-citation
Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb
Quaresma, A. J. C., Bugai, A., & Barborič, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw585 · Cited by 134
2-Aryl-5-carboxytetrazole as a New Photoaffinity Label for Drug Target Identification
Herner, A., Marjanovic, J., Lewandowski, T. M., Marin, V. L., Patterson, M. J. S., Miesbauer, L. J., Ready, D. B., Williams, J. D., Vasudevan, A., & Lin, Q. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06645 · Cited by 134
Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
Fontanals-Cirera, B., Hasson, D., Vardabasso, C., Micco, R. D., Agrawal, P. K., Chowdhury, A. H., Gantz, M., de Pablos-Aragoneses, A., Morgenstern, A., Wu, P., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.004 · Cited by 134
Objective assessment of cancer genes for drug discovery
Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 133
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
Zhang, H., Qi, J., Reyes, J. M., Li, L., Rao, P. K., Li, F., Lin, C. Y., Perry, J. A., Lawlor, M. A., Alexander Joel Federation, et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0164 · Cited by 133
Self-citation
Targeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 133
Epigenetic Control of ImmunityPreprint
Busslinger, M., & Tarakhovsky, A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019307 · Cited by 133
Chemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Self-citation
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
Filippakopoulos, P., Picaud, S., Fedorov, O., Keller, M., Wrobel, M. N., Morgenstern, O., Bracher, F., & Knapp, S. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.080 · Cited by 132
Self-citation
High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy
Bugyei‐Twum, A., Advani, A., Advani, S. L., Zhang, Y., Thai, K., Kelly, D. J., & Connelly, K. A. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-89 · Cited by 132
Potent and selective bivalent inhibitors of BET bromodomains
Waring, M. J., Chen, H., Rabow, A. A., Walker, G. E., Bobby, R., Boiko, S., Bradbury, R. H., Callis, R. J., Clark, E. A., Dale, I. L., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2210 · Cited by 132
Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals
Schwörer, S., Becker, F., Feller, C., Baig, A. H., Köber, U., Henze, H., Kraus, J. M., Xin, B., Lechel, A., Lipka, D. B., et al. (2016) · Nature · doi:10.1038/nature20603 · Cited by 132
BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice
Cheung, K., Lu, G., Sharma, R., Vincek, A. S., Zhang, R., Plotnikov, A. N., Zhang, F., Zhang, Q., Ju, Y., Hu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615601114 · Cited by 132
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Vidler, L. R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H. L., Brown, N., Knapp, S., & Hoelder, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011302 · Cited by 131
Self-citation
Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer
Bedi, U., Mishra, V. K., Wasilewski, D., Scheel, C., & Johnsen, S. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1875 · Cited by 131
Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer
Teng, S., Li, Y. E., Yang, M., Qi, R., Huang, Y., Wang, Q., Zhang, Y., Chen, S., Li, S., Lin, K., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0259-z · Cited by 131
Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review
Dzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 132
A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 130
Targeting PP2A in cancer: Combination therapies
Mazhar, S., Taylor, S. E., Sangodkar, J., & Narla, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.020 · Cited by 130
An Epigenetic Role of Mitochondria in Cancer
Liu, Y., Chen, C., Wang, X., Sun, Y., Zhang, J., Chen, J., & Shi, Y. (2022) · Cells · doi:10.3390/cells11162518 · Cited by 131
Bromodomains and Their Pharmacological Inhibitors
Gallenkamp, D., Gelato, K. A., Haendler, B., & Weinmann, H. (2014) · ChemMedChem · doi:10.1002/cmdc.201300434 · Cited by 129
The Bromodomain: A New Target in Emerging Epigenetic Medicine
Smith, S. G., & Zhou, M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00831 · Cited by 130
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma
Nakagawa, M., Shaffer, A. L., Ceribelli, M., Zhang, M., Wright, G. W., Huang, D. W., Xiao, W., Powell, J. I., Petrus, M. N., Yang, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.014 · Cited by 129
Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Pantuck, A. J., Lee, D., Kee, T. W., Wang, P., Lakhotia, S., Silverman, M. H., Mathis, C., Drakaki, A., Belldegrun, A. S., Ho, C., et al. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800104 · Cited by 129
Radius measurement via super-resolution microscopy enables the development of a variable radii proximity labeling platform
Oakley, J. V., Buksh, B. F., Fernández, D. F., Oblinsky, D. G., Seath, C. P., Geri, J. B., Scholes, G. D., & MacMillan, D. W. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203027119 · Cited by 135
Epigenetic Regulation of Monocyte and Macrophage Function
Hoeksema, M. A., & de Winther, M. P. J. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6695 · Cited by 128
Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy
Xu, X., Saw, P. E., Tao, W., Li, Y., Ji, X., Yu, M., Mahmoudi, M., Rasmussen, J., Ayyash, D., Zhou, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b01571 · Cited by 128
Structural Basis and Specificity of Acetylated Transcription Factor GATA1 Recognition by BET Family Bromodomain Protein Brd3
Gamsjaeger, R., Webb, S. R., Lamonica, J. M., Billin, A. N., Blobel, G. A., & Mackay, J. P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05413-11 · Cited by 128
New Strategies in the Treatment of Multiple Myeloma
Munshi, N. C., & Anderson, K. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1881 · Cited by 127
Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis
Tang, X., Peng, R., Phillips, J. E., Deguzman, J., Ren, Y., Apparsundaram, S., Luo, Q., Bauer, C. M. T., Fuentes, M. E., DeMartino, J. A., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.020 · Cited by 126
BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses
Dey, A., Yang, W., Gégonne, A., Nishiyama, A., Pan, R., Yagi, R., Grinberg, A., Finkelman, F. D., Pfeifer, K. E., Zhu, J., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100293 · Cited by 128
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review
Yang, C., Qin, C., Bai, L., & Wang, S. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.04.001 · Cited by 126
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells
Debruyne, D. N., Dries, R., Sengupta, S., Seruggia, D., Gao, Y., Sharma, B., Huang, H., Moreau, L. A., McLane, M., Day, D. S., et al. (2019) · Nature · doi:10.1038/s41586-019-1472-0 · Cited by 126
Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF
Bennett, J. M., Fedorov, O., Tallant, C., Monteiro, O., Meier, J. C., Gamble, V., Savitsky, P. A., Nunez-Alonso, G. A., Haendler, B., Rogers, C. M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00458 · Cited by 126
Self-citation
Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation
Nadeem, A., Al-Harbi, N. O., Al-Harbi, M. M., El‐Sherbeeny, A. M., Ahmad, S. F., Siddiqui, N. M., Ansari, M. A., Zoheir, K. M. A., Attia, S. M., Alhosaini, K. A., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.001 · Cited by 126
Chromatin as an expansive canvas for chemical biology
Fierz, B., & Muir, T. W. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.938 · Cited by 125
The application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 127
Self-citation
Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1
Tao, Y., Remillard, D., Vinogradova, E. V., Yokoyama, M., Banchenko, S., Schwefel, D., Melillo, B. N., Schreiber, S. L., Zhang, X., & Cravatt, B. F. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08964 · Cited by 127
Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy
Liang, K., Smith, E. R., Aoi, Y., Stoltz, K. L., Katagi, H., Woodfin, A. R., Rendleman, E. J., Marshall, S. A., Murray, D. C., Wang, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.027 · Cited by 124
The Importance of Diagnosing NUT Midline Carcinoma
French, C. A. (2013) · Head and Neck Pathology · doi:10.1007/s12105-013-0428-1 · Cited by 124
Self-citation
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Bui, M. H., Li, X., Albert, D. H., Li, L., Lam, L. T., Faivre, E. J., Warder, S. E., Huang, X., Wilcox, D. M., Donawho, C. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1793 · Cited by 124
Self-citation
A chemical toolbox for the study of bromodomains and epigenetic signaling
Wu, Q., Heidenreich, D. J., Zhou, S., Ackloo, S. Z., Krämer, A., Nakka, K. K., Lima‐Fernandes, E., Deblois, G., Duan, S., Vellanki, R. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09672-2 · Cited by 124
Self-citation
Structural Conservation of Distinctive N-terminal Acetylation-Dependent Interactions across a Family of Mammalian NEDD8 Ligation Enzymes
Monda, J. K., Scott, D. C., Miller, D. J., Lydeard, J. R., King, D., Harper, J. W., Bennett, E. J., & Schulman, B. A. (2012) · Structure · doi:10.1016/j.str.2012.10.013 · Cited by 124
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
Baker, E. K., Taylor, S., Gupte, A., Sharp, P. P., Walia, M., Walsh, N. C., Zannettino, A. C. W., Chalk, A. M., Burns, C. J., & Walkley, C. R. (2015) · Scientific Reports · doi:10.1038/srep10120 · Cited by 123
Non-kinase targets of protein kinase inhibitors
Munoz, L. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.266 · Cited by 123
The tale of a tail: histone H4 acetylation and the repair of DNA breaks
Dhar, S., Gürsoy-Yüzügüllü, Ö., Parasuram, R., & Price, B. D. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0284 · Cited by 123
Brd4’s Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1
Wu, T., Kamikawa, Y. F., & Donohoe, M. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.003 · Cited by 123
Why Some Targets Benefit from beyond Rule of Five Drugs
Egbert, M. E., Whitty, A., Keserű, G. M., & Vajda, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01732 · Cited by 123
Small-Molecule Ligands of Methyl-Lysine Binding Proteins
Herold, J. M., Wigle, T. J., Norris, J. L., Lam, R., Korboukh, V. K., Gao, C., Ingerman, L. A., Kireev, D., Senisterra, G. A., Vedadi, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200045v · Cited by 122
Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum
Evans, A. G., French, C. A., Cameron, M. J., Fletcher, C. D. �., Jackman, D. M., Lathan, C. S., & Sholl, L. M. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318258f03b · Cited by 122
Self-citation
BET bromodomain inhibitors: a patent review
Garnier, J., Sharp, P. P., & Burns, C. J. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859244 · Cited by 122
Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain
Zhao, L., Cao, D., Chen, T., Wang, Y.-Q., Miao, Z., Xu, Y., Chen, W., Wang, X., Li, Y., Du, Z., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301793a · Cited by 122
Self-citation
The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Shahbazi, J., Liu, P. Y., Atmadibrata, B., Bradner, J. E., Marshall, G. M., Lock, R. B., & Liu, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1666 · Cited by 122
Self-citation
Genital human papillomavirus infections: current and prospective therapies
Stanley, M. (2012) · Journal of General Virology · doi:10.1099/vir.0.039677-0 · Cited by 121
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
Li, G.-Q., Guo, W.-Z., Zhang, Y., Seng, J.-J., Zhang, H., Ma, X.-X., Zhang, G., Li, J., Yan, B., Tang, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6275 · Cited by 121
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain
Law, R. P., Atkinson, S. J., Bamborough, P., Chung, C., Demont, E. H., Gordon, L. J., Lindon, M. J., Prinjha, R. K., Watson, A. J. B., & Hirst, D. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01666 · Cited by 121
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 122
What makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.008 · Cited by 121
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
Joshi, S., & Durden, D. L. (2019) · Journal of Oncology · doi:10.1155/2019/5245034 · Cited by 120
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
Jia, Y., Chng, W. J., & Zhou, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0757-y · Cited by 120
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Shapiro, G. I., LoRusso, P. M., Dowlati, A., Do, K. T., Jacobson, C. A., Vaishampayan, U. N., Weise, A. M., Caimi, P. F., Eder, J. P., French, C. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01180-1 · Cited by 120
Self-citation
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Damerell, V., Pepper, M. S., & Prince, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00647-8 · Cited by 120
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
Zhao, X. L., Lwin, T., Zhang, X., Huang, A., Wang, J., Márquez, V. E., Chen‐Kiang, S., Dalton, W. S., Sotomayor, E., & Tao, J. (2013) · Leukemia · doi:10.1038/leu.2013.94 · Cited by 119
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response
Hussong, M., Börno, S. T., Kerick, M., Wunderlich, A., Franz, A. M., Sültmann, H., Timmermann, B., Lehrach, H., Hirsch‐Kauffmann, M., & Schweiger, M. R. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.157 · Cited by 119
A Series of Potent CREBBP Bromodomain Ligands Reveals an Induced‐Fit Pocket Stabilized by a Cation–π Interaction
Rooney, T. P. C., Filippakopoulos, P., Fedorov, O., Picaud, S., Cortopassi, W. A., Hay, D. A., Martin, S., Tumber, A., Rogers, C. M., Philpott, M., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402750 · Cited by 119
Self-citation
Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma
Venkataraman, S., Alimova, I. N., Balakrishnan, I., Harris, P. S., Birks, D. K., Griesinger, A. M., Amani, V. M., Cristiano, B., Remke, M., Taylor, M. D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1659 · Cited by 119
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 119
The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Dittmann, A., Werner, T., Chung, C., Savitski, M. M., Savitski, M. F., Grandi, P., Hopf, C., Lindon, M. J., Neubauer, G., Prinjha, R. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400789e · Cited by 119
Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
Andrews, F. H., Singh, A. R., Joshi, S., Smith, C. A., Morales, G. A., Garlich, J. R., Durden, D. L., & Kutateladze, T. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613091114 · Cited by 119
Tendon-derived cathepsin K–expressing progenitor cells activate Hedgehog signaling to drive heterotopic ossification
Feng, H., Xing, W., Han, Y., Sun, J., Kong, M., Gao, B., Yang, Y., Yin, Z., Chen, X., Zhao, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132518 · Cited by 119
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
Wang, W., Tang, Y., Xiao, Q., Lee, W. C., Cheng, B., Niu, Z., Oguz, G., Feng, M., Lee, P. L., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24687-4 · Cited by 119
Polycomb-mediated silencing in neuroendocrine prostate cancer
Clermont, P., Lin, D., Crea, F., Wu, R. C., Xue, H., Wang, Y., Thu, K. L., Lam, W. L., Collins, C. C., Wang, Y. Z., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0074-4 · Cited by 118
Self-citation
A Combination of H2A.Z and H4 Acetylation Recruits Brd2 to Chromatin during Transcriptional Activation
Draker, R., Ng, M. K., Sarcinella, E., Ignatchenko, V., Kislinger, T., & Cheung, P. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003047 · Cited by 118
Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression
Zhou, B., Mu, J., Gong, Y., Lu, C., Zhao, Y., He, T., & Qin, Z. (2016) · Redox Biology · doi:10.1016/j.redox.2016.12.031 · Cited by 118
MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia
Prange, K. H. M., Mandoli, A., Kuznetsova, T., Wang, S.-Y., Sotoca, A. M., Marneth, A. E., van der Reijden, B. A., Stunnenberg, H. G., & Martens, J. H. A. (2017) · Oncogene · doi:10.1038/onc.2016.488 · Cited by 118
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
Cohen, A. J., Saiakhova, A., Corradin, O., Luppino, J. M., Lovrenert, K., Bartels, C. F., Morrow, J. J., Mack, S. C., Dhillon, G. K., Beard, L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14400 · Cited by 118
Self-citation
Small molecule photocatalysis enables drug target identification via energy transfer
Trowbridge, A., Seath, C. P., Rodriguez‐Rivera, F. P., Li, B. X., Dul, B. E., Schwaid, A. G., Buksh, B. F., Geri, J. B., Oakley, J. V., Fadeyi, O., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208077119 · Cited by 121
Targeting protein–protein interactions, a wide open field for drug design
Bakail, M., & Ochsenbein, F. (2016) · Comptes Rendus. Chimie · doi:10.1016/j.crci.2015.12.004 · Cited by 117
Epigenomic regulation of oncogenesis by chromatin remodeling
Kumar, R., Li, D.-Q., Müller, S., & Knapp, S. (2016) · Oncogene · doi:10.1038/onc.2015.513 · Cited by 117
Self-citation
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Gilham, D., Wasiak, S., Tsujikawa, L. M., Halliday, C., Norek, K., Patel, R. G., Kulikowski, E., Johansson, J., Sweeney, M., & Wong, N. C. W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.036 · Cited by 118
Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
Bechter, O. E., & Schöffski, P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107479 · Cited by 117
Signal pathways and precision therapy of small-cell lung cancer
Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 117

Authors: Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., & Bradner, J. E.
Affiliations: University of Oxford (GB)
Harvard University (US)
University of Notre Dame (US)
Brigham and Women's Hospital (US)
Boston Children's Hospital (US)
Corresponding author: Knapp, Stefan
Bradner, James E.
ORCID: Filippakopoulos, Panagis
Qi, Jun
Picaud, Sarah
Shen, Yao
Fedorov, Oleg
Hickman, Tyler T.
Philpott, Martin
Munro, Shonagh
McKeown, Michael R.
Wang, Yuchuan
Schwartz, Brian
Heightman, Tom D.
French, Christopher A.
Wiest, Olaf
Kung, Andrew L.
Knapp, Stefan
Bradner, James E.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-09-24
Volume: 468
Issue: 7327
Pages: 1067-1073
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09504
PMC: PMC3010259
OpenAlex: W2041535798
Cited by: 4,262
References: 42
Citations by year: 2026: 217 · 2025: 307 · 2024: 304 · 2023: 307 · 2022: 309 · 2021: 323 · 2020: 340 · 2019: 323 · 2018: 303 · 2017: 306 · 2016: 334 · 2015: 279 · 2014: 246 · 2013: 177 · 2012: 117
FWCI: 48.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
Funders: Wellcome Trust
Cancer Research UK (13058)
U.S. Public Health Service (T32-075762)
Canadian Institutes of Health Research
National Cancer Institute (K08CA128972)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: BET inhibitors, JQ1, BRD4, epigenetic reader protein, protein-protein interaction inhibition, squamous cell carcinoma, histone acetylation, co-crystal structure, chemical probes, transcriptional regulation
MeSH terms: Bromodomain Containing Proteins, Amino Acid Sequence, Animals, Azirines, Binding Sites, Carcinoma, Squamous Cell, Cell Differentiation, Chromatin, Dihydropyridines, Female, Humans, Mice, Nude, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Protein Binding, Recombinant Proteins, Skin Neoplasms, Stereoisomerism, Transcription Factors, Sequence Alignment, Protein Structure, Tertiary, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective inhibition of BET bromodomains

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks